As protein kinases represent one of the most successful class of drug target in the field of cancer, we identified eight protein kinases in our list, including CSNK1G2 (casein kinase 1 gamma 2), ACVR1 (activin A receptor type 1), PAK2, and AKT3 (V-Akt murine thymoma viral oncogene homolog 3), AKT2, CAMK2A (calcium/calmodulin-dependent protein kinase II alpha), MLKL (mixed lineage kinase domain-like), CDK14 (cyclin-dependent kinase 14), and CDK17 (Fig. 2b). The gene discussed is AKT3; the disease is cancer.